Research Paper Volume 13, Issue 6 pp 8643—8664

Figure 2. TGFβ1, CTGF, COL1, and FN were upregulated in the membrane after antiVEGF-treated. (A) TGFβ1, CTGF, α-SMA, FN and COL1 proliferative membrane immunofluorescence results in PDR patients without anti-VEGF treatment. (B) TGFβ1, CTGF, α-SMA, FN and COL1 proliferative membrane immunofluorescence results in PDR patients with anti-VEGF treatment. Vimentin, as an internal reference. DAPI, the tracer shows the nuclear position of the fluorescent agent 4',6-diamidino-2-phenylindole (magnification: ×10). (C) The levels of TGFβ1, CTGF, COL1, FN, and α-SMA were analyzed using ImageJ. Expression of TGFβ1, CTGF, COL1, and FN were significantly higher in the membranes obtained from antiVEGF-treated PDR patients than in the membranes obtained from untreated PDR patients. Data are expressed as mean ± SEM. * means P < 0.05, **means P < 0.01, *** means P < 0.001.